Health knowledge made personal
Join this community!
› Share page:
Search posts:

Phase III COPD Trials Show Benefits of Pairing Novartis’ LAMA with LABA Therapy

Posted Feb 11 2011 8:41am

Novartis reported on two Phase III studies demonstrating that treating COPD using its marketed once-daily OnBrez® Breezhaler® (indacaterol) in addition to tiotropium (Boehringer Ingelheim’s long-acting anti-muscarinic [LAMA] drug Spiriva® HandiHaler®) improves lung function to a significantly greater degree than tiotropium therapy alone. The Intrust 1 and Intrust 2 studies were matching 12-week placebo-controlled studies involving a total of 2,276 patients with moderate-to-severe COPD. The primary endpoint was improvements in lung function measured by FEV1.

Novartis claims Onbrez Breezhaler is the only marketed once-daily, long-acting beta-2 agonsit (LABA). “Previous studies have confirmed the efficacy of Onbrez Breezhaler as monotherapy, and these data show the potential for additional lung function benefits when two of the leading classes of treatment for COPD are combined,”… more>>>

Post a comment
Write a comment:

Related Searches